Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases


Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment of a broad range of diseases, including but not limited to Huntington's, amyotrophic lateral sclerosis, ischemia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis. Not surprisingly this enormous potential has resulted in at least three caspase 1 inhibitors entering clinical trials (VX-740, IDN-6556, and VX-765) in recent years.

Potential Commercial Applications: Competitive Advantages:
  • Potential therapeutic for a broad range of autoimmune diseases
  • Potential therapeutic for a broad range of inflammatory diseases
 


Development Stage:
Early stage

Inventors:

Craig Thomas (NCATS)  ➽ more inventions...

Matthew Boxer (NCATS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,365,612 issued 2016-06-14
US Application No. 61/299,790
PCT Application No. PCT/US2011/022744

Publications:
Boxer MB, Quinn AM, Shen M, Jadhav A, Leister W, Simeonov A, Auld DS, Thomas CJ. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. Chem Med Chem., accepted.

Collaboration Opportunity:

The NIH Chemical Genomics Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize appropriate lead compounds described in U.S. Provisional Application No. 61/299,790. Please contact Dr. Craig J. Thomas via e-mail (craigt@nhgri.nih.gov) for more information.


Licensing Contact:
Suryanarayana Vepa, Ph.D.
Email: sury.vepa@nih.gov
Phone: 301-827-7181

OTT Reference No: E-308-2009-0
Updated: Mar 11, 2010